Low-Grade Neuroepithelial Tumor, NOS

Diseases /

Low-Grade Neuroepithelial Tumor, NOS

Back to Diseases List

Associated Genetic Biomarkers

ALK
ALK Fusion
ARAF
ARAF Mutation
BRAF
BRAF Fusion
BRAF Mutation
BRAF V600A
BRAF V600D
BRAF V600E
BRAF V600G
BRAF V600K
BRAF V600M
BRAF V600R
CRKL
CRKL Mutation
FGFR1
FGFR1 Mutation
FGFR2
FGFR2 Mutation

FGFR3
FGFR3 Mutation
H3F3A
H3F3A Codon 34 Missense
H3F3A Codon 35 Missense
H3F3A K27M
H3F3A K28M
HRAS
HRAS Mutation
IDH1

IDH1 Mutation
IDH2
IDH2 Mutation
KRAS
KRAS Mutation
MAP2K1
MAP2K1 Mutation
MAP2K2
MAP2K2 Mutation
MAP2K4

MAP2K4 Loss
MAP2K4 Mutation
MAP3K1
MAP3K1 Loss
MAP3K1 Mutation
MAPK1
MAPK1 Mutation
MYB
MYB Mutation
MYBL1

MYBL1 Mutation
NF1
NF1 Loss
NF1 Mutation
NF2
NF2 Loss
NF2 Mutation
NRAS
NRAS Mutation
NTRK1

NTRK1 Fusion
NTRK2
NTRK2 Fusion
NTRK3
NTRK3 Fusion
PTPN1
PTPN1 Mutation
RAF1
RAF1 Mutation
ROS1

ROS1 Fusion
SOS1
SOS1 Mutation
SRC
SRC Mutation

Overview

Low-grade neuroepithelial tumor, NOSs most frequently harbor alterations in BRAF, TFEB, TET2, SPRY4, and SDHC [2].

Most Commonly Altered Genes in Low-Grade Neuroepithelial Tumor, NOS

BRAF Mutation, BRAF Exon 15 Mutation, BRAF V600E, BRAF Codon 600 Missense, and TFEB A135T are the most common alterations in low-grade neuroepithelial tumor, NOS [2].

Top Alterations in Low-Grade Neuroepithelial Tumor, NOS

Clinical Trials

View Clinical Trials for Low-Grade Neuroepithelial Tumor, NOS

There is 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are completed or closed. Of the trial that contains low-grade neuroepithelial tumor, NOS as an inclusion criterion, 1 is phase 1/phase 2 (1 open).

ARAF, BRAF, and CRKL are the most frequent gene inclusion criteria for low-grade neuroepithelial tumor, NOS clinical trials [3].

Trials Investigating Low-Grade Neuroepithelial Tumor, NOS by Gene and Recruiting Status

Mirdametinib is the most common intervention in low-grade neuroepithelial tumor, NOS clinical trials.

Drugs Being Investigated in Low-Grade Neuroepithelial Tumor, NOS Trials by Recruiting Status

Significant Genes in Low-Grade Neuroepithelial Tumor, NOS

ARAF +

ARAF is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF +

BRAF is altered in 45.45% of low-grade neuroepithelial tumor, NOS patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CRKL +

CRKL is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 +

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 +

FGFR2 is altered in 9.09% of low-grade neuroepithelial tumor, NOS patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR3 +

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS +

HRAS is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KRAS +

KRAS is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K1 +

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 +

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 +

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 +

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 +

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYB +

MYB is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MYB status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYBL1 +

MYBL1 is altered in 12.5% of low-grade neuroepithelial tumor, NOS patients [2].

MYBL1 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MYBL1 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF1 +

NF1 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF2 +

NF2 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS +

NRAS is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTPN1 +

PTPN1 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains PTPN1 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAF1 +

RAF1 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SOS1 +

SOS1 is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SRC +

SRC is an inclusion eligibility criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains SRC status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

Disease Details

Parent(s)

Neuroepithelial Neoplasm

OncoTree Name

Low-Grade Neuroepithelial Tumor

OncoTree Code

LGNET

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Low-Grade Neuroepithelial Tumor, NOS

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Low-Grade Neuroepithelial Tumor, NOS

Disease Details

References

About

Molecular Medicine

Content Types